This month, we received a new award from the National Institute of Allergy and Infectious Diseases (NIH) to study interventional approaches to improve the targeting of artemisinin combination therapy to individuals with confirmed malaria infection. This new project builds on Continue reading New grant to improve targeting of subsidized antimalarials sold over-the-counter
ExactDx in PLoS Medicine! The primary results of our community-based cluster randomized trial in western Kenya. The main points: In most malaria-endemic countries, first-line antimalarials called artemisinin combination therapies, or ACTs, are available over the counter in retail medicine outlets Continue reading Improving antimalarial use at the community level
This week, the Kenya National Malaria Control Programme hosted the 3rd Kenya Malaria Forum in Nairobi. ExactDx team presented in two session. Joseph Kipkoech (above) presented results from the Malaria Voucher Study to demonstrate how targeting of antimalarials could be Continue reading ExactDx at the Kenya National Malaria Forum!
|